NO332465B1 - Anvendelse av loselige, muterte CTLA4-molekyler for fremstilling av et medikament for a inhibere avstotning av oycelletransplantat. - Google Patents

Info

Publication number

NO332465B1

NO332465B1 NO20035176A NO20035176A NO332465B1 NO 332465 B1 NO332465 B1 NO 332465B1 NO 20035176 A NO20035176 A NO 20035176A NO 20035176 A NO20035176 A NO 20035176A NO 332465 B1 NO332465 B1 NO 332465B1

Authority

NO

Norway

Prior art keywords

soluble

ctla4

use according

antibodies reactive

mutated

Prior art date

2001-05-23

Links

• Espacenet
• Global Dossier
• Discuss

• 101000889276 Homo sapiens Cytotoxic T-lymphocyte protein 4 Proteins 0.000 title claims abstract description 272
• 102100039498 Cytotoxic T-lymphocyte protein 4 Human genes 0.000 title claims abstract description 271
• 206010052779 Transplant rejections Diseases 0.000 title claims abstract description 13
• 239000003814 drug Substances 0.000 title claims description 22
• 229940079593 drug Drugs 0.000 title claims description 15
• 238000002360 preparation method Methods 0.000 title description 4
• 210000000287 oocyte Anatomy 0.000 title 1
• 210000004153 islets of langerhan Anatomy 0.000 claims abstract description 26
• 206010012601 diabetes mellitus Diseases 0.000 claims abstract description 23
• 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims abstract description 18
• 208000001072 type 2 diabetes mellitus Diseases 0.000 claims abstract description 6
• 210000001744 T-lymphocyte Anatomy 0.000 claims description 77
• 230000027455 binding Effects 0.000 claims description 59
• 102100027222 T-lymphocyte activation antigen CD80 Human genes 0.000 claims description 53
• 101000914484 Homo sapiens T-lymphocyte activation antigen CD80 Proteins 0.000 claims description 47
• 238000002054 transplantation Methods 0.000 claims description 47
• 230000035772 mutation Effects 0.000 claims description 43
• 230000001506 immunosuppresive effect Effects 0.000 claims description 42
• 108060003951 Immunoglobulin Proteins 0.000 claims description 41
• 102000018358 immunoglobulin Human genes 0.000 claims description 41
• 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 claims description 38
• 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 claims description 38
• 239000003446 ligand Substances 0.000 claims description 35
• 239000003795 chemical substances by application Substances 0.000 claims description 23
• 229960002930 sirolimus Drugs 0.000 claims description 22
• QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 claims description 22
• ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 claims description 20
• QJJXYPPXXYFBGM-LFZNUXCKSA-N Tacrolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1\C=C(/C)[C@@H]1[C@H](C)[C@@H](O)CC(=O)[C@H](CC=C)/C=C(C)/C[C@H](C)C[C@H](OC)[C@H]([C@H](C[C@H]2C)OC)O[C@@]2(O)C(=O)C(=O)N2CCCC[C@H]2C(=O)O1 QJJXYPPXXYFBGM-LFZNUXCKSA-N 0.000 claims description 17
• 150000001875 compounds Chemical class 0.000 claims description 17
• 101150013553 CD40 gene Proteins 0.000 claims description 15
• 102100032937 CD40 ligand Human genes 0.000 claims description 15
• 102100040245 Tumor necrosis factor receptor superfamily member 5 Human genes 0.000 claims description 15
• -1 ICOS Proteins 0.000 claims description 14
• 108010074328 Interferon-gamma Proteins 0.000 claims description 14
• 241000282693 Cercopithecidae Species 0.000 claims description 12
• PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 claims description 12
• 108010036949 Cyclosporine Proteins 0.000 claims description 12
• 101000868215 Homo sapiens CD40 ligand Proteins 0.000 claims description 12
• 230000005764 inhibitory process Effects 0.000 claims description 12
• 102100037850 Interferon gamma Human genes 0.000 claims description 11
• FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 claims description 10
• 229960000485 methotrexate Drugs 0.000 claims description 10
• 102000005962 receptors Human genes 0.000 claims description 10
• 108020003175 receptors Proteins 0.000 claims description 10
• 229960001265 ciclosporin Drugs 0.000 claims description 9
• 102000004127 Cytokines Human genes 0.000 claims description 8
• 108090000695 Cytokines Proteins 0.000 claims description 8
• 102000051628 Interleukin-1 receptor antagonist Human genes 0.000 claims description 8
• 108010002350 Interleukin-2 Proteins 0.000 claims description 8
• 229930182912 cyclosporin Natural products 0.000 claims description 8
• 230000002519 immonomodulatory effect Effects 0.000 claims description 8
• 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 claims description 8
• CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 claims description 7
• 101000759376 Escherichia phage Mu Tail sheath protein Proteins 0.000 claims description 7
• 108010008165 Etanercept Proteins 0.000 claims description 7
• 108010009817 Immunoglobulin Constant Regions Proteins 0.000 claims description 7
• 102000009786 Immunoglobulin Constant Regions Human genes 0.000 claims description 7
• 108700021006 Interleukin-1 receptor antagonist Proteins 0.000 claims description 7
• 229960002170 azathioprine Drugs 0.000 claims description 7
• LMEKQMALGUDUQG-UHFFFAOYSA-N azathioprine Chemical compound CN1C=NC([N+]([O-])=O)=C1SC1=NC=NC2=C1NC=N2 LMEKQMALGUDUQG-UHFFFAOYSA-N 0.000 claims description 7
• 210000002798 bone marrow cell Anatomy 0.000 claims description 7
• 210000000265 leukocyte Anatomy 0.000 claims description 7
• HMLGSIZOMSVISS-ONJSNURVSA-N (7r)-7-[[(2z)-2-(2-amino-1,3-thiazol-4-yl)-2-(2,2-dimethylpropanoyloxymethoxyimino)acetyl]amino]-3-ethenyl-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid Chemical compound N([C@@H]1C(N2C(=C(C=C)CSC21)C(O)=O)=O)C(=O)\C(=N/OCOC(=O)C(C)(C)C)C1=CSC(N)=N1 HMLGSIZOMSVISS-ONJSNURVSA-N 0.000 claims description 6
• 102000006395 Globulins Human genes 0.000 claims description 6
• 108010044091 Globulins Proteins 0.000 claims description 6
• 108010008212 Integrin alpha4beta1 Proteins 0.000 claims description 6
• 102100025390 Integrin beta-2 Human genes 0.000 claims description 6
• 102100025237 T-cell surface antigen CD2 Human genes 0.000 claims description 6
• 229960004238 anakinra Drugs 0.000 claims description 6
• 239000003124 biologic agent Substances 0.000 claims description 6
• 239000003246 corticosteroid Substances 0.000 claims description 6
• 229960000403 etanercept Drugs 0.000 claims description 6
• XXSMGPRMXLTPCZ-UHFFFAOYSA-N hydroxychloroquine Chemical compound ClC1=CC=C2C(NC(C)CCCN(CCO)CC)=CC=NC2=C1 XXSMGPRMXLTPCZ-UHFFFAOYSA-N 0.000 claims description 6
• 229960000598 infliximab Drugs 0.000 claims description 6
• 239000003112 inhibitor Substances 0.000 claims description 6
• 108040006849 interleukin-2 receptor activity proteins Proteins 0.000 claims description 6
• VHOGYURTWQBHIL-UHFFFAOYSA-N leflunomide Chemical compound O1N=CC(C(=O)NC=2C=CC(=CC=2)C(F)(F)F)=C1C VHOGYURTWQBHIL-UHFFFAOYSA-N 0.000 claims description 6
• VVNCNSJFMMFHPL-VKHMYHEASA-N D-penicillamine Chemical compound CC(C)(S)[C@@H](N)C(O)=O VVNCNSJFMMFHPL-VKHMYHEASA-N 0.000 claims description 5
• 241000283973 Oryctolagus cuniculus Species 0.000 claims description 5
• 239000005557 antagonist Substances 0.000 claims description 5
• 229960004397 cyclophosphamide Drugs 0.000 claims description 5
• 239000012636 effector Substances 0.000 claims description 5
• 229960004171 hydroxychloroquine Drugs 0.000 claims description 5
• 230000002757 inflammatory effect Effects 0.000 claims description 5
• 229960000681 leflunomide Drugs 0.000 claims description 5
• 210000004698 lymphocyte Anatomy 0.000 claims description 5
• 238000004519 manufacturing process Methods 0.000 claims description 5
• RTGDFNSFWBGLEC-SYZQJQIISA-N mycophenolate mofetil Chemical compound COC1=C(C)C=2COC(=O)C=2C(O)=C1C\C=C(/C)CCC(=O)OCCN1CCOCC1 RTGDFNSFWBGLEC-SYZQJQIISA-N 0.000 claims description 5
• 229960001639 penicillamine Drugs 0.000 claims description 5
• WHTVZRBIWZFKQO-AWEZNQCLSA-N (S)-chloroquine Chemical compound ClC1=CC=C2C(N[C@@H](C)CCCN(CC)CC)=CC=NC2=C1 WHTVZRBIWZFKQO-AWEZNQCLSA-N 0.000 claims description 4
• 102100032912 CD44 antigen Human genes 0.000 claims description 4
• 108010024212 E-Selectin Proteins 0.000 claims description 4
• 102100023471 E-selectin Human genes 0.000 claims description 4
• 101000868273 Homo sapiens CD44 antigen Proteins 0.000 claims description 4
• 101000935043 Homo sapiens Integrin beta-1 Proteins 0.000 claims description 4
• 101000581981 Homo sapiens Neural cell adhesion molecule 1 Proteins 0.000 claims description 4
• 102100025304 Integrin beta-1 Human genes 0.000 claims description 4
• 108010092694 L-Selectin Proteins 0.000 claims description 4
• 102000016551 L-selectin Human genes 0.000 claims description 4
• 108010064548 Lymphocyte Function-Associated Antigen-1 Proteins 0.000 claims description 4
• 102100027347 Neural cell adhesion molecule 1 Human genes 0.000 claims description 4
• 108010000134 Vascular Cell Adhesion Molecule-1 Proteins 0.000 claims description 4
• 102100023543 Vascular cell adhesion protein 1 Human genes 0.000 claims description 4
• 229960004669 basiliximab Drugs 0.000 claims description 4
• 229960003677 chloroquine Drugs 0.000 claims description 4
• WHTVZRBIWZFKQO-UHFFFAOYSA-N chloroquine Natural products ClC1=CC=C2C(NC(C)CCCN(CC)CC)=CC=NC2=C1 WHTVZRBIWZFKQO-UHFFFAOYSA-N 0.000 claims description 4
• 229960001334 corticosteroids Drugs 0.000 claims description 4
• 229960004866 mycophenolate mofetil Drugs 0.000 claims description 4
• 241000283073 Equus caballus Species 0.000 claims description 3
• 101001055144 Homo sapiens Interleukin-2 receptor subunit alpha Proteins 0.000 claims description 3
• 101000851370 Homo sapiens Tumor necrosis factor receptor superfamily member 9 Proteins 0.000 claims description 3
• 101150052863 THY1 gene Proteins 0.000 claims description 3
• 102100036856 Tumor necrosis factor receptor superfamily member 9 Human genes 0.000 claims description 3
• HPNSFSBZBAHARI-UHFFFAOYSA-N micophenolic acid Natural products OC1=C(CC=C(C)CCC(O)=O)C(OC)=C(C)C2=C1C(=O)OC2 HPNSFSBZBAHARI-UHFFFAOYSA-N 0.000 claims description 3
• 229960000951 mycophenolic acid Drugs 0.000 claims description 3
• HPNSFSBZBAHARI-RUDMXATFSA-N mycophenolic acid Chemical compound OC1=C(C\C=C(/C)CCC(O)=O)C(OC)=C(C)C2=C1C(=O)OC2 HPNSFSBZBAHARI-RUDMXATFSA-N 0.000 claims description 3
• 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 claims description 3
• UEJJHQNACJXSKW-UHFFFAOYSA-N 2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione Chemical compound O=C1C2=CC=CC=C2C(=O)N1C1CCC(=O)NC1=O UEJJHQNACJXSKW-UHFFFAOYSA-N 0.000 claims description 2
• 102100027207 CD27 antigen Human genes 0.000 claims description 2
• 102100036008 CD48 antigen Human genes 0.000 claims description 2
• 102000004631 Calcineurin Human genes 0.000 claims description 2
• 108010042955 Calcineurin Proteins 0.000 claims description 2
• 108010072051 Glatiramer Acetate Proteins 0.000 claims description 2
• 101000914511 Homo sapiens CD27 antigen Proteins 0.000 claims description 2
• 101000716130 Homo sapiens CD48 antigen Proteins 0.000 claims description 2
• 101000935040 Homo sapiens Integrin beta-2 Proteins 0.000 claims description 2
• 101001057504 Homo sapiens Interferon-stimulated gene 20 kDa protein Proteins 0.000 claims description 2
• 101001063392 Homo sapiens Lymphocyte function-associated antigen 3 Proteins 0.000 claims description 2
• 101000738771 Homo sapiens Receptor-type tyrosine-protein phosphatase C Proteins 0.000 claims description 2
• 101000914496 Homo sapiens T-cell antigen CD7 Proteins 0.000 claims description 2
• 108010064593 Intercellular Adhesion Molecule-1 Proteins 0.000 claims description 2
• 108010064600 Intercellular Adhesion Molecule-3 Proteins 0.000 claims description 2
• 102100037877 Intercellular adhesion molecule 1 Human genes 0.000 claims description 2
• 102100037872 Intercellular adhesion molecule 2 Human genes 0.000 claims description 2
• 101710148794 Intercellular adhesion molecule 2 Proteins 0.000 claims description 2
• 102100037871 Intercellular adhesion molecule 3 Human genes 0.000 claims description 2
• 108010005716 Interferon beta-1a Proteins 0.000 claims description 2
• 102100030984 Lymphocyte function-associated antigen 3 Human genes 0.000 claims description 2
• QXKHYNVANLEOEG-UHFFFAOYSA-N Methoxsalen Chemical compound C1=CC(=O)OC2=C1C=C1C=COC1=C2OC QXKHYNVANLEOEG-UHFFFAOYSA-N 0.000 claims description 2
• HZQDCMWJEBCWBR-UUOKFMHZSA-N Mizoribine Chemical compound OC1=C(C(=O)N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 HZQDCMWJEBCWBR-UUOKFMHZSA-N 0.000 claims description 2
• 102100037422 Receptor-type tyrosine-protein phosphatase C Human genes 0.000 claims description 2
• 102100027208 T-cell antigen CD7 Human genes 0.000 claims description 2
• 101710165202 T-cell surface antigen CD2 Proteins 0.000 claims description 2
• 102100022153 Tumor necrosis factor receptor superfamily member 4 Human genes 0.000 claims description 2
• 101710165473 Tumor necrosis factor receptor superfamily member 4 Proteins 0.000 claims description 2
• PCWZKQSKUXXDDJ-UHFFFAOYSA-N Xanthotoxin Natural products COCc1c2OC(=O)C=Cc2cc3ccoc13 PCWZKQSKUXXDDJ-UHFFFAOYSA-N 0.000 claims description 2
• FHEAIOHRHQGZPC-KIWGSFCNSA-N acetic acid;(2s)-2-amino-3-(4-hydroxyphenyl)propanoic acid;(2s)-2-aminopentanedioic acid;(2s)-2-aminopropanoic acid;(2s)-2,6-diaminohexanoic acid Chemical compound CC(O)=O.C[C@H](N)C(O)=O.NCCCC[C@H](N)C(O)=O.OC(=O)[C@@H](N)CCC(O)=O.OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 FHEAIOHRHQGZPC-KIWGSFCNSA-N 0.000 claims description 2
• 230000003110 anti-inflammatory effect Effects 0.000 claims description 2
• 229940092117 atgam Drugs 0.000 claims description 2
• 229940046731 calcineurin inhibitors Drugs 0.000 claims description 2
• 229960000556 fingolimod Drugs 0.000 claims description 2
• KKGQTZUTZRNORY-UHFFFAOYSA-N fingolimod Chemical compound CCCCCCCCC1=CC=C(CCC(N)(CO)CO)C=C1 KKGQTZUTZRNORY-UHFFFAOYSA-N 0.000 claims description 2
• 229960003776 glatiramer acetate Drugs 0.000 claims description 2
• 229960004461 interferon beta-1a Drugs 0.000 claims description 2
• 229960004469 methoxsalen Drugs 0.000 claims description 2
• ZAHQPTJLOCWVPG-UHFFFAOYSA-N mitoxantrone dihydrochloride Chemical compound Cl.Cl.O=C1C2=C(O)C=CC(O)=C2C(=O)C2=C1C(NCCNCCO)=CC=C2NCCNCCO ZAHQPTJLOCWVPG-UHFFFAOYSA-N 0.000 claims description 2
• 229960004169 mitoxantrone hydrochloride Drugs 0.000 claims description 2
• 229950000844 mizoribine Drugs 0.000 claims description 2
• 229960004618 prednisone Drugs 0.000 claims description 2
• XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 claims description 2
• 239000002412 selectin antagonist Substances 0.000 claims description 2
• 229960003433 thalidomide Drugs 0.000 claims description 2
• 101710088998 Response regulator inhibitor for tor operon Proteins 0.000 claims 2
• 102100027268 Interferon-stimulated gene 20 kDa protein Human genes 0.000 claims 1
• 229960000074 biopharmaceutical Drugs 0.000 claims 1
• 238000000034 method Methods 0.000 abstract description 61
• 238000011282 treatment Methods 0.000 abstract description 22
• 230000002401 inhibitory effect Effects 0.000 abstract description 10
• 210000004027 cell Anatomy 0.000 description 79
• 125000003295 alanine group Chemical group N[C@@H](C)C(=O)* 0.000 description 47
• NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 46
• WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 44
• 235000013922 glutamic acid Nutrition 0.000 description 44
• 239000004220 glutamic acid Substances 0.000 description 44
• 235000004279 alanine Nutrition 0.000 description 43
• 235000003704 aspartic acid Nutrition 0.000 description 43
• CKLJMWTZIZZHCS-REOHCLBHSA-N aspartic acid group Chemical group N[C@@H](CC(=O)O)C(=O)O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 43
• OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 43
• 125000001360 methionine group Chemical group N[C@@H](CCSC)C(=O)* 0.000 description 35
• 125000000291 glutamic acid group Chemical group N[C@@H](CCC(O)=O)C(=O)* 0.000 description 33
• 241001465754 Metazoa Species 0.000 description 31
• 235000001014 amino acid Nutrition 0.000 description 31
• 210000001519 tissue Anatomy 0.000 description 31
• 239000013598 vector Substances 0.000 description 29
• KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 28
• 210000001185 bone marrow Anatomy 0.000 description 28
• 125000003275 alpha amino acid group Chemical group 0.000 description 27
• 229940024606 amino acid Drugs 0.000 description 27
• 150000001413 amino acids Chemical class 0.000 description 27
• 239000003018 immunosuppressive agent Substances 0.000 description 26
• 229930182817 methionine Natural products 0.000 description 26
• 108090000623 proteins and genes Proteins 0.000 description 25
• 102000004877 Insulin Human genes 0.000 description 23
• 108090001061 Insulin Proteins 0.000 description 23
• 229940125721 immunosuppressive agent Drugs 0.000 description 23
• 229940125396 insulin Drugs 0.000 description 23
• 230000003993 interaction Effects 0.000 description 23
• MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 22
• 210000000056 organ Anatomy 0.000 description 22
• ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 21
• 235000018102 proteins Nutrition 0.000 description 20
• 102000004169 proteins and genes Human genes 0.000 description 20
• 230000004044 response Effects 0.000 description 18
• 108010076504 Protein Sorting Signals Proteins 0.000 description 17
• 239000002773 nucleotide Substances 0.000 description 17
• 125000003729 nucleotide group Chemical group 0.000 description 17
• 125000003607 serino group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C(O[H])([H])[H] 0.000 description 17
• WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 16
• 210000004978 chinese hamster ovary cell Anatomy 0.000 description 16
• 239000012634 fragment Substances 0.000 description 16
• 239000008103 glucose Substances 0.000 description 16
• 238000002703 mutagenesis Methods 0.000 description 16
• 231100000350 mutagenesis Toxicity 0.000 description 16
• 239000000203 mixture Substances 0.000 description 14
• QJJXYPPXXYFBGM-SHYZHZOCSA-N tacrolimus Natural products CO[C@H]1C[C@H](CC[C@@H]1O)C=C(C)[C@H]2OC(=O)[C@H]3CCCCN3C(=O)C(=O)[C@@]4(O)O[C@@H]([C@H](C[C@H]4C)OC)[C@@H](C[C@H](C)CC(=C[C@@H](CC=C)C(=O)C[C@H](O)[C@H]2C)C)OC QJJXYPPXXYFBGM-SHYZHZOCSA-N 0.000 description 14
• 238000002560 therapeutic procedure Methods 0.000 description 14
• OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 14
• 239000004472 Lysine Substances 0.000 description 13
• 235000018417 cysteine Nutrition 0.000 description 13
• 108020001507 fusion proteins Proteins 0.000 description 13
• 102000037865 fusion proteins Human genes 0.000 description 13
• 238000012360 testing method Methods 0.000 description 13
• 108020004705 Codon Proteins 0.000 description 12
• 108020004414 DNA Proteins 0.000 description 12
• 230000028993 immune response Effects 0.000 description 12
• 125000001909 leucine group Chemical group [H]N(*)C(C(*)=O)C([H])([H])C(C([H])([H])[H])C([H])([H])[H] 0.000 description 12
• 229960001967 tacrolimus Drugs 0.000 description 12
• 125000000539 amino acid group Chemical group 0.000 description 11
• 210000004369 blood Anatomy 0.000 description 11
• 239000008280 blood Substances 0.000 description 11
• 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 11
• 230000000694 effects Effects 0.000 description 11
• 208000026278 immune system disease Diseases 0.000 description 11
• 238000001990 intravenous administration Methods 0.000 description 11
• 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 11
• 230000004083 survival effect Effects 0.000 description 11
• 230000007704 transition Effects 0.000 description 11
• DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical group NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 10
• 108091028043 Nucleic acid sequence Proteins 0.000 description 10
• 239000000969 carrier Substances 0.000 description 10
• 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 10
• ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 10
• 239000008194 pharmaceutical composition Substances 0.000 description 10
• 208000035408 type 1 diabetes mellitus 1 Diseases 0.000 description 10
• 208000023275 Autoimmune disease Diseases 0.000 description 9
• 102000004190 Enzymes Human genes 0.000 description 9
• 108090000790 Enzymes Proteins 0.000 description 9
• 240000004808 Saccharomyces cerevisiae Species 0.000 description 9
• 235000014680 Saccharomyces cerevisiae Nutrition 0.000 description 9
• 239000000427 antigen Substances 0.000 description 9
• 108091007433 antigens Proteins 0.000 description 9
• 102000036639 antigens Human genes 0.000 description 9
• 230000037396 body weight Effects 0.000 description 9
• 230000008859 change Effects 0.000 description 9
• 201000010099 disease Diseases 0.000 description 9
• 238000002198 surface plasmon resonance spectroscopy Methods 0.000 description 9
• ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 8
• 238000004458 analytical method Methods 0.000 description 8
• 230000000903 blocking effect Effects 0.000 description 8
• 230000008614 cellular interaction Effects 0.000 description 8
• 230000006870 function Effects 0.000 description 8
• 230000006698 induction Effects 0.000 description 8
• 230000001939 inductive effect Effects 0.000 description 8
• 108020004707 nucleic acids Proteins 0.000 description 8
• 102000039446 nucleic acids Human genes 0.000 description 8
• 150000007523 nucleic acids Chemical class 0.000 description 8
• 210000000496 pancreas Anatomy 0.000 description 8
• 108090000765 processed proteins & peptides Proteins 0.000 description 8
• 238000012216 screening Methods 0.000 description 8
• 230000019491 signal transduction Effects 0.000 description 8
• 108010035053 B7-1 Antigen Proteins 0.000 description 7
• 108010021800 B7-2 Antigen Proteins 0.000 description 7
• 102000007697 B7-2 Antigen Human genes 0.000 description 7
• 239000004471 Glycine Chemical group 0.000 description 7
• OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 7
• 108060008682 Tumor Necrosis Factor Proteins 0.000 description 7
• 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 7
• 210000000612 antigen-presenting cell Anatomy 0.000 description 7
• XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 7
• 230000014509 gene expression Effects 0.000 description 7
• 230000001965 increasing effect Effects 0.000 description 7
• 230000001404 mediated effect Effects 0.000 description 7
• 239000002609 medium Substances 0.000 description 7
• 239000000047 product Substances 0.000 description 7
• 230000035755 proliferation Effects 0.000 description 7
• 238000006467 substitution reaction Methods 0.000 description 7
• 229940122739 Calcineurin inhibitor Drugs 0.000 description 6
• 101710192106 Calcineurin-binding protein cabin-1 Proteins 0.000 description 6
• 102100024123 Calcineurin-binding protein cabin-1 Human genes 0.000 description 6
• 241000196324 Embryophyta Species 0.000 description 6
• 206010062016 Immunosuppression Diseases 0.000 description 6
• QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 6
• 102000004140 Oncostatin M Human genes 0.000 description 6
• 108090000630 Oncostatin M Proteins 0.000 description 6
• ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 6
• 230000000735 allogeneic effect Effects 0.000 description 6
• 230000005875 antibody response Effects 0.000 description 6
• 238000010494 dissociation reaction Methods 0.000 description 6
• 230000005593 dissociations Effects 0.000 description 6
• 238000005538 encapsulation Methods 0.000 description 6
• 239000013604 expression vector Substances 0.000 description 6
• 238000007446 glucose tolerance test Methods 0.000 description 6
• 150000002343 gold Chemical class 0.000 description 6
• 239000001963 growth medium Substances 0.000 description 6
• 125000001500 prolyl group Chemical group [H]N1C([H])(C(=O)[*])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 6
• 230000002829 reductive effect Effects 0.000 description 6
• 229940124597 therapeutic agent Drugs 0.000 description 6
• 125000001493 tyrosinyl group Chemical group [H]OC1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 6
• 239000004475 Arginine Substances 0.000 description 5
• 230000006052 T cell proliferation Effects 0.000 description 5
• 230000005867 T cell response Effects 0.000 description 5
• AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 5
• 239000004473 Threonine Substances 0.000 description 5
• KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 5
• ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 5
• 238000003149 assay kit Methods 0.000 description 5
• 210000003719 b-lymphocyte Anatomy 0.000 description 5
• LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 5
• 239000000499 gel Substances 0.000 description 5
• 239000003862 glucocorticoid Substances 0.000 description 5
• 125000003630 glycyl group Chemical group [H]N([H])C([H])([H])C(*)=O 0.000 description 5
• 210000000987 immune system Anatomy 0.000 description 5
• 238000007912 intraperitoneal administration Methods 0.000 description 5
• 229960000310 isoleucine Drugs 0.000 description 5
• AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 5
• 239000002953 phosphate buffered saline Substances 0.000 description 5
• 230000001105 regulatory effect Effects 0.000 description 5
• 230000010076 replication Effects 0.000 description 5
• 230000002441 reversible effect Effects 0.000 description 5
• 150000003839 salts Chemical class 0.000 description 5
• 238000001542 size-exclusion chromatography Methods 0.000 description 5
• NCEXYHBECQHGNR-QZQOTICOSA-N sulfasalazine Chemical compound C1=C(O)C(C(=O)O)=CC(\N=N\C=2C=CC(=CC=2)S(=O)(=O)NC=2N=CC=CC=2)=C1 NCEXYHBECQHGNR-QZQOTICOSA-N 0.000 description 5
• 208000024891 symptom Diseases 0.000 description 5
• 230000001225 therapeutic effect Effects 0.000 description 5
• 239000004474 valine Substances 0.000 description 5
• 125000002987 valine group Chemical group [H]N([H])C([H])(C(*)=O)C([H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 5
• XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
• 241000894006 Bacteria Species 0.000 description 4
• 241000283707 Capra Species 0.000 description 4
• 229930105110 Cyclosporin A Natural products 0.000 description 4
• 102000000588 Interleukin-2 Human genes 0.000 description 4
• UETNIIAIRMUTSM-UHFFFAOYSA-N Jacareubin Natural products CC1(C)OC2=CC3Oc4c(O)c(O)ccc4C(=O)C3C(=C2C=C1)O UETNIIAIRMUTSM-UHFFFAOYSA-N 0.000 description 4
• WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical group OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 4
• QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 4
• 241000282560 Macaca mulatta Species 0.000 description 4
• 241000699666 Mus <mouse, genus> Species 0.000 description 4
• 108010047620 Phytohemagglutinins Proteins 0.000 description 4
• QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 4
• 230000002776 aggregation Effects 0.000 description 4
• 238000004220 aggregation Methods 0.000 description 4
• 239000002775 capsule Substances 0.000 description 4
• 210000000170 cell membrane Anatomy 0.000 description 4
• 230000001684 chronic effect Effects 0.000 description 4
• 239000002299 complementary DNA Substances 0.000 description 4
• 230000000139 costimulatory effect Effects 0.000 description 4
• 238000011161 development Methods 0.000 description 4
• 210000001198 duodenum Anatomy 0.000 description 4
• 239000000839 emulsion Substances 0.000 description 4
• 238000002474 experimental method Methods 0.000 description 4
• 238000001802 infusion Methods 0.000 description 4
• 238000002347 injection Methods 0.000 description 4
• 239000007924 injection Substances 0.000 description 4
• 238000002955 isolation Methods 0.000 description 4
• 125000000741 isoleucyl group Chemical group [H]N([H])C(C(C([H])([H])[H])C([H])([H])C([H])([H])[H])C(=O)O* 0.000 description 4
• 239000002502 liposome Substances 0.000 description 4
• 239000007788 liquid Substances 0.000 description 4
• 239000003921 oil Substances 0.000 description 4
• 230000001885 phytohemagglutinin Effects 0.000 description 4
• 229920001184 polypeptide Polymers 0.000 description 4
• 230000003389 potentiating effect Effects 0.000 description 4
• 239000013615 primer Substances 0.000 description 4
• 102000004196 processed proteins & peptides Human genes 0.000 description 4
• 238000009256 replacement therapy Methods 0.000 description 4
• 230000028327 secretion Effects 0.000 description 4
• 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 4
• 239000000243 solution Substances 0.000 description 4
• 229960001940 sulfasalazine Drugs 0.000 description 4
• NCEXYHBECQHGNR-UHFFFAOYSA-N sulfasalazine Natural products C1=C(O)C(C(=O)O)=CC(N=NC=2C=CC(=CC=2)S(=O)(=O)NC=2N=CC=CC=2)=C1 NCEXYHBECQHGNR-UHFFFAOYSA-N 0.000 description 4
• 239000000829 suppository Substances 0.000 description 4
• 229940037128 systemic glucocorticoids Drugs 0.000 description 4
• 230000001988 toxicity Effects 0.000 description 4
• 231100000419 toxicity Toxicity 0.000 description 4
• 125000000143 2-carboxyethyl group Chemical group [H]OC(=O)C([H])([H])C([H])([H])* 0.000 description 3
• 102100039358 3-hydroxyacyl-CoA dehydrogenase type-2 Human genes 0.000 description 3
• 108700028369 Alleles Proteins 0.000 description 3
• DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 3
• 102000005738 B7 Antigens Human genes 0.000 description 3
• 108010045634 B7 Antigens Proteins 0.000 description 3
• 108010062433 CD28 Antigens Proteins 0.000 description 3
• 102000010910 CD28 Antigens Human genes 0.000 description 3
• 108010029697 CD40 Ligand Proteins 0.000 description 3
• 101001035740 Homo sapiens 3-hydroxyacyl-CoA dehydrogenase type-2 Proteins 0.000 description 3
• 101000946850 Homo sapiens T-lymphocyte activation antigen CD86 Proteins 0.000 description 3
• 102000008070 Interferon-gamma Human genes 0.000 description 3
• 108090000978 Interleukin-4 Proteins 0.000 description 3
• 102000004388 Interleukin-4 Human genes 0.000 description 3
• DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 3
• AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 3
• 230000004913 activation Effects 0.000 description 3
• 238000007792 addition Methods 0.000 description 3
• 239000002260 anti-inflammatory agent Substances 0.000 description 3
• 230000010056 antibody-dependent cellular cytotoxicity Effects 0.000 description 3
• 235000009582 asparagine Nutrition 0.000 description 3
• 229960001230 asparagine Drugs 0.000 description 3
• 210000004899 c-terminal region Anatomy 0.000 description 3
• 230000036755 cellular response Effects 0.000 description 3
• 238000003776 cleavage reaction Methods 0.000 description 3
• 230000000295 complement effect Effects 0.000 description 3
• 230000004540 complement-dependent cytotoxicity Effects 0.000 description 3
• 230000016396 cytokine production Effects 0.000 description 3
• 230000006378 damage Effects 0.000 description 3
• 238000002224 dissection Methods 0.000 description 3
• 239000003937 drug carrier Substances 0.000 description 3
• 238000004520 electroporation Methods 0.000 description 3
• 238000000684 flow cytometry Methods 0.000 description 3
• MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 3
• 230000036541 health Effects 0.000 description 3
• 230000002209 hydrophobic effect Effects 0.000 description 3
• 230000036039 immunity Effects 0.000 description 3
• 229940124589 immunosuppressive drug Drugs 0.000 description 3
• 238000007918 intramuscular administration Methods 0.000 description 3
• 210000004185 liver Anatomy 0.000 description 3
• 230000007774 longterm Effects 0.000 description 3
• 210000004962 mammalian cell Anatomy 0.000 description 3
• 239000003550 marker Substances 0.000 description 3
• 239000000463 material Substances 0.000 description 3
• 239000000178 monomer Substances 0.000 description 3
• 210000005259 peripheral blood Anatomy 0.000 description 3
• 239000011886 peripheral blood Substances 0.000 description 3
• 239000013612 plasmid Substances 0.000 description 3
• 230000037452 priming Effects 0.000 description 3
• 210000001236 prokaryotic cell Anatomy 0.000 description 3
• 238000001742 protein purification Methods 0.000 description 3
• 230000002285 radioactive effect Effects 0.000 description 3
• 238000002708 random mutagenesis Methods 0.000 description 3
• 230000007017 scission Effects 0.000 description 3
• 235000002639 sodium chloride Nutrition 0.000 description 3
• 238000007920 subcutaneous administration Methods 0.000 description 3
• 238000001890 transfection Methods 0.000 description 3
• 210000003462 vein Anatomy 0.000 description 3
• 208000004998 Abdominal Pain Diseases 0.000 description 2
• RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 2
• IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
• 241000713842 Avian sarcoma virus Species 0.000 description 2
• 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
• 108010021064 CTLA-4 Antigen Proteins 0.000 description 2
• 102000008203 CTLA-4 Antigen Human genes 0.000 description 2
• 241000701489 Cauliflower mosaic virus Species 0.000 description 2
• 208000002881 Colic Diseases 0.000 description 2
• 102100037364 Craniofacial development protein 1 Human genes 0.000 description 2
• 229920002307 Dextran Polymers 0.000 description 2
• 108090000204 Dipeptidase 1 Proteins 0.000 description 2
• 101150013359 E7 gene Proteins 0.000 description 2
• 108010087819 Fc receptors Proteins 0.000 description 2
• 102000009109 Fc receptors Human genes 0.000 description 2
• 241000282326 Felis catus Species 0.000 description 2
• 108010010803 Gelatin Proteins 0.000 description 2
• 244000068988 Glycine max Species 0.000 description 2
• 235000010469 Glycine max Nutrition 0.000 description 2
• 208000009329 Graft vs Host Disease Diseases 0.000 description 2
• HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 2
• 101000798109 Homo sapiens Melanotransferrin Proteins 0.000 description 2
• 108091006905 Human Serum Albumin Proteins 0.000 description 2
• 102000008100 Human Serum Albumin Human genes 0.000 description 2
• 102100034353 Integrase Human genes 0.000 description 2
• 102100026878 Interleukin-2 receptor subunit alpha Human genes 0.000 description 2
• 241000829100 Macaca mulatta polyomavirus 1 Species 0.000 description 2
• FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 2
• 102100032239 Melanotransferrin Human genes 0.000 description 2
• 241000699670 Mus sp. Species 0.000 description 2
• 108010021466 Mutant Proteins Proteins 0.000 description 2
• 102000008300 Mutant Proteins Human genes 0.000 description 2
• 238000005481 NMR spectroscopy Methods 0.000 description 2
• 238000011887 Necropsy Methods 0.000 description 2
• 206010028980 Neoplasm Diseases 0.000 description 2
• 240000007594 Oryza sativa Species 0.000 description 2
• 235000007164 Oryza sativa Nutrition 0.000 description 2
• 241001631646 Papillomaviridae Species 0.000 description 2
• 241000009328 Perro Species 0.000 description 2
• 241000288906 Primates Species 0.000 description 2
• 201000004681 Psoriasis Diseases 0.000 description 2
• 241000700159 Rattus Species 0.000 description 2
• 208000025747 Rheumatic disease Diseases 0.000 description 2
• 229920002472 Starch Polymers 0.000 description 2
• 235000021355 Stearic acid Nutrition 0.000 description 2
• 241000282898 Sus scrofa Species 0.000 description 2
• IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 2
• 241000702295 Tomato golden mosaic virus Species 0.000 description 2
• 240000008042 Zea mays Species 0.000 description 2
• 235000002017 Zea mays subsp mays Nutrition 0.000 description 2
• 239000008186 active pharmaceutical agent Substances 0.000 description 2
• 239000000654 additive Substances 0.000 description 2
• 239000002671 adjuvant Substances 0.000 description 2
• 239000012491 analyte Substances 0.000 description 2
• 210000004102 animal cell Anatomy 0.000 description 2
• 239000003242 anti bacterial agent Substances 0.000 description 2
• 229940124599 anti-inflammatory drug Drugs 0.000 description 2
• 229940088710 antibiotic agent Drugs 0.000 description 2
• 238000013459 approach Methods 0.000 description 2
• 125000000637 arginyl group Chemical group N[C@@H](CCCNC(N)=N)C(=O)* 0.000 description 2
• 238000003556 assay Methods 0.000 description 2
• 230000006472 autoimmune response Effects 0.000 description 2
• WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
• 102000006635 beta-lactamase Human genes 0.000 description 2
• CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 2
• 235000013539 calcium stearate Nutrition 0.000 description 2
• 239000008116 calcium stearate Substances 0.000 description 2
• 230000001413 cellular effect Effects 0.000 description 2
• 239000003153 chemical reaction reagent Substances 0.000 description 2
• 239000004927 clay Substances 0.000 description 2
• 210000001953 common bile duct Anatomy 0.000 description 2
• 238000007796 conventional method Methods 0.000 description 2
• 229940111134 coxibs Drugs 0.000 description 2
• DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 2
• 239000003255 cyclooxygenase 2 inhibitor Substances 0.000 description 2
• 238000007405 data analysis Methods 0.000 description 2
• 230000034994 death Effects 0.000 description 2
• 230000003247 decreasing effect Effects 0.000 description 2
• 238000012217 deletion Methods 0.000 description 2
• 230000037430 deletion Effects 0.000 description 2
• 238000010586 diagram Methods 0.000 description 2
• 239000000539 dimer Substances 0.000 description 2
• 229940088679 drug related substance Drugs 0.000 description 2
• 108010078428 env Gene Products Proteins 0.000 description 2
• 210000003527 eukaryotic cell Anatomy 0.000 description 2
• 239000013613 expression plasmid Substances 0.000 description 2
• 239000012091 fetal bovine serum Substances 0.000 description 2
• 239000000796 flavoring agent Substances 0.000 description 2
• 235000019634 flavors Nutrition 0.000 description 2
• 230000004927 fusion Effects 0.000 description 2
• 229940044627 gamma-interferon Drugs 0.000 description 2
• 239000008273 gelatin Substances 0.000 description 2
• 229920000159 gelatin Polymers 0.000 description 2
• 235000019322 gelatine Nutrition 0.000 description 2
• 235000011852 gelatine desserts Nutrition 0.000 description 2
• 150000002334 glycols Chemical class 0.000 description 2
• 230000002414 glycolytic effect Effects 0.000 description 2
• 208000024908 graft versus host disease Diseases 0.000 description 2
• UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical group O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 description 2
• 230000003394 haemopoietic effect Effects 0.000 description 2
• 210000002216 heart Anatomy 0.000 description 2
• 229960002897 heparin Drugs 0.000 description 2
• 229920000669 heparin Polymers 0.000 description 2
• 102000054189 human CD80 Human genes 0.000 description 2
• 102000049849 human CD86 Human genes 0.000 description 2
• 229940124622 immune-modulator drug Drugs 0.000 description 2
• 208000025095 immunoproliferative disease Diseases 0.000 description 2
• 230000001771 impaired effect Effects 0.000 description 2
• 238000000338 in vitro Methods 0.000 description 2
• 238000011534 incubation Methods 0.000 description 2
• CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 description 2
• 210000003734 kidney Anatomy 0.000 description 2
• 230000003907 kidney function Effects 0.000 description 2
• 206010025135 lupus erythematosus Diseases 0.000 description 2
• 229910052749 magnesium Inorganic materials 0.000 description 2
• HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Substances [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
• 235000019359 magnesium stearate Nutrition 0.000 description 2
• 229940091250 magnesium supplement Drugs 0.000 description 2
• MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 2
• 238000000520 microinjection Methods 0.000 description 2
• 235000013336 milk Nutrition 0.000 description 2
• 239000008267 milk Substances 0.000 description 2
• 210000004080 milk Anatomy 0.000 description 2
• QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 2
• OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 2
• 235000019198 oils Nutrition 0.000 description 2
• 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 2
• COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 2
• COLNVLDHVKWLRT-QMMMGPOBSA-N phenylalanine group Chemical group N[C@@H](CC1=CC=CC=C1)C(=O)O COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 2
• 229920000642 polymer Polymers 0.000 description 2
• 230000001323 posttranslational effect Effects 0.000 description 2
• 230000008569 process Effects 0.000 description 2
• 238000012545 processing Methods 0.000 description 2
• 230000009696 proliferative response Effects 0.000 description 2
• 210000001938 protoplast Anatomy 0.000 description 2
• 229940099538 rapamune Drugs 0.000 description 2
• 229940116176 remicade Drugs 0.000 description 2
• 238000011160 research Methods 0.000 description 2
• 206010039073 rheumatoid arthritis Diseases 0.000 description 2
• 235000009566 rice Nutrition 0.000 description 2
• 239000005060 rubber Substances 0.000 description 2
• WVYADZUPLLSGPU-UHFFFAOYSA-N salsalate Chemical compound OC(=O)C1=CC=CC=C1OC(=O)C1=CC=CC=C1O WVYADZUPLLSGPU-UHFFFAOYSA-N 0.000 description 2
• 238000000926 separation method Methods 0.000 description 2
• 229940115586 simulect Drugs 0.000 description 2
• 238000009097 single-agent therapy Methods 0.000 description 2
• 239000002904 solvent Substances 0.000 description 2
• 238000010186 staining Methods 0.000 description 2
• 235000019698 starch Nutrition 0.000 description 2
• 239000008107 starch Substances 0.000 description 2
• 239000008117 stearic acid Substances 0.000 description 2
• 239000008174 sterile solution Substances 0.000 description 2
• 230000000638 stimulation Effects 0.000 description 2
• 239000000126 substance Substances 0.000 description 2
• 235000000346 sugar Nutrition 0.000 description 2
• 230000001629 suppression Effects 0.000 description 2
• 238000003786 synthesis reaction Methods 0.000 description 2
• 239000000454 talc Substances 0.000 description 2
• 235000012222 talc Nutrition 0.000 description 2
• 229910052623 talc Inorganic materials 0.000 description 2
• 125000000341 threoninyl group Chemical group [H]OC([H])(C([H])([H])[H])C([H])(N([H])[H])C(*)=O 0.000 description 2
• 229940104230 thymidine Drugs 0.000 description 2
• RWQNBRDOKXIBIV-UHFFFAOYSA-N thymine Chemical group CC1=CNC(=O)NC1=O RWQNBRDOKXIBIV-UHFFFAOYSA-N 0.000 description 2
• 230000008354 tissue degradation Effects 0.000 description 2
• 230000000699 topical effect Effects 0.000 description 2
• 239000003053 toxin Substances 0.000 description 2
• 231100000765 toxin Toxicity 0.000 description 2
• 108700012359 toxins Proteins 0.000 description 2
• 235000015112 vegetable and seed oil Nutrition 0.000 description 2
• 235000019871 vegetable fat Nutrition 0.000 description 2
• DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 2
• MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical group OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 1
• RDJGLLICXDHJDY-NSHDSACASA-N (2s)-2-(3-phenoxyphenyl)propanoic acid Chemical compound OC(=O)[C@@H](C)C1=CC=CC(OC=2C=CC=CC=2)=C1 RDJGLLICXDHJDY-NSHDSACASA-N 0.000 description 1
• LJRDOKAZOAKLDU-UDXJMMFXSA-N (2s,3s,4r,5r,6r)-5-amino-2-(aminomethyl)-6-[(2r,3s,4r,5s)-5-[(1r,2r,3s,5r,6s)-3,5-diamino-2-[(2s,3r,4r,5s,6r)-3-amino-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-6-hydroxycyclohexyl]oxy-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl]oxyoxane-3,4-diol;sulfuric ac Chemical compound OS(O)(=O)=O.N[C@@H]1[C@@H](O)[C@H](O)[C@H](CN)O[C@@H]1O[C@H]1[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](N)C[C@@H](N)[C@@H]2O)O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)N)O[C@@H]1CO LJRDOKAZOAKLDU-UDXJMMFXSA-N 0.000 description 1
• TVYLLZQTGLZFBW-ZBFHGGJFSA-N (R,R)-tramadol Chemical compound COC1=CC=CC([C@]2(O)[C@H](CCCC2)CN(C)C)=C1 TVYLLZQTGLZFBW-ZBFHGGJFSA-N 0.000 description 1
• 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
• UOFGSWVZMUXXIY-UHFFFAOYSA-N 1,5-Diphenyl-3-thiocarbazone Chemical compound C=1C=CC=CC=1N=NC(=S)NNC1=CC=CC=C1 UOFGSWVZMUXXIY-UHFFFAOYSA-N 0.000 description 1
• IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
• GZCWLCBFPRFLKL-UHFFFAOYSA-N 1-prop-2-ynoxypropan-2-ol Chemical compound CC(O)COCC#C GZCWLCBFPRFLKL-UHFFFAOYSA-N 0.000 description 1
• OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
• IDINUJSAMVOPCM-UHFFFAOYSA-N 15-Deoxyspergualin Natural products NCCCNCCCCNC(=O)C(O)NC(=O)CCCCCCN=C(N)N IDINUJSAMVOPCM-UHFFFAOYSA-N 0.000 description 1
• CHHHXKFHOYLYRE-UHFFFAOYSA-M 2,4-Hexadienoic acid, potassium salt (1:1), (2E,4E)- Chemical compound [K+].CC=CC=CC([O-])=O CHHHXKFHOYLYRE-UHFFFAOYSA-M 0.000 description 1
• ATOKJLVNLKSYTM-UHFFFAOYSA-N 3-(ethyliminomethylideneamino)-n,n-dimethylpropan-1-amine;1-hydroxypyrrolidine-2,5-dione Chemical compound ON1C(=O)CCC1=O.CCN=C=NCCCN(C)C ATOKJLVNLKSYTM-UHFFFAOYSA-N 0.000 description 1
• OSJPPGNTCRNQQC-UWTATZPHSA-N 3-phospho-D-glyceric acid Chemical compound OC(=O)[C@H](O)COP(O)(O)=O OSJPPGNTCRNQQC-UWTATZPHSA-N 0.000 description 1
• QFVHZQCOUORWEI-UHFFFAOYSA-N 4-[(4-anilino-5-sulfonaphthalen-1-yl)diazenyl]-5-hydroxynaphthalene-2,7-disulfonic acid Chemical compound C=12C(O)=CC(S(O)(=O)=O)=CC2=CC(S(O)(=O)=O)=CC=1N=NC(C1=CC=CC(=C11)S(O)(=O)=O)=CC=C1NC1=CC=CC=C1 QFVHZQCOUORWEI-UHFFFAOYSA-N 0.000 description 1
• BSYNRYMUTXBXSQ-FOQJRBATSA-N 59096-14-9 Chemical compound CC(=O)OC1=CC=CC=C1[14C](O)=O BSYNRYMUTXBXSQ-FOQJRBATSA-N 0.000 description 1
• OXEUETBFKVCRNP-UHFFFAOYSA-N 9-ethyl-3-carbazolamine Chemical compound NC1=CC=C2N(CC)C3=CC=CC=C3C2=C1 OXEUETBFKVCRNP-UHFFFAOYSA-N 0.000 description 1
• 102000013563 Acid Phosphatase Human genes 0.000 description 1
• 108010051457 Acid Phosphatase Proteins 0.000 description 1
• HRPVXLWXLXDGHG-UHFFFAOYSA-N Acrylamide Chemical compound NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 description 1
• 208000026872 Addison Disease Diseases 0.000 description 1
• 241000589158 Agrobacterium Species 0.000 description 1
• 101710187573 Alcohol dehydrogenase 2 Proteins 0.000 description 1
• 101710133776 Alcohol dehydrogenase class-3 Proteins 0.000 description 1
• 240000003291 Armoracia rusticana Species 0.000 description 1
• 208000004300 Atrophic Gastritis Diseases 0.000 description 1
• 208000023328 Basedow disease Diseases 0.000 description 1
• DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 1
• 208000008439 Biliary Liver Cirrhosis Diseases 0.000 description 1
• 208000033222 Biliary cirrhosis primary Diseases 0.000 description 1
• 241000283690 Bos taurus Species 0.000 description 1
• 241000701822 Bovine papillomavirus Species 0.000 description 1
• 101100495256 Caenorhabditis elegans mat-3 gene Proteins 0.000 description 1
• 208000004672 Cardiovascular Infections Diseases 0.000 description 1
• 208000024172 Cardiovascular disease Diseases 0.000 description 1
• 102000014914 Carrier Proteins Human genes 0.000 description 1
• 206010008909 Chronic Hepatitis Diseases 0.000 description 1
• 108091026890 Coding region Proteins 0.000 description 1
• 206010009900 Colitis ulcerative Diseases 0.000 description 1
• 108020004635 Complementary DNA Proteins 0.000 description 1
• 241000699802 Cricetulus griseus Species 0.000 description 1
• 208000011231 Crohn disease Diseases 0.000 description 1
• 239000003155 DNA primer Substances 0.000 description 1
• 238000001712 DNA sequencing Methods 0.000 description 1
• 206010011968 Decreased immune responsiveness Diseases 0.000 description 1
• 241000388186 Deltapapillomavirus 4 Species 0.000 description 1
• 241000702421 Dependoparvovirus Species 0.000 description 1
• KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
• 238000002965 ELISA Methods 0.000 description 1
• 241000588724 Escherichia coli Species 0.000 description 1
• 241000206602 Eukaryota Species 0.000 description 1
• 108050001049 Extracellular proteins Proteins 0.000 description 1
• 208000016937 Extranodal nasal NK/T cell lymphoma Diseases 0.000 description 1
• 238000001134 F-test Methods 0.000 description 1
• 238000012413 Fluorescence activated cell sorting analysis Methods 0.000 description 1
• 208000036495 Gastritis atrophic Diseases 0.000 description 1
• 108700039691 Genetic Promoter Regions Proteins 0.000 description 1
• 208000002705 Glucose Intolerance Diseases 0.000 description 1
• 206010018429 Glucose tolerance impaired Diseases 0.000 description 1
• 208000024869 Goodpasture syndrome Diseases 0.000 description 1
• 208000015023 Graves' disease Diseases 0.000 description 1
• 102100030595 HLA class II histocompatibility antigen gamma chain Human genes 0.000 description 1
• 101001120495 Haloarcula marismortui (strain ATCC 43049 / DSM 3752 / JCM 8966 / VKM B-1809) 30S ribosomal protein S17 Proteins 0.000 description 1
• 101000811217 Haloarcula marismortui (strain ATCC 43049 / DSM 3752 / JCM 8966 / VKM B-1809) 30S ribosomal protein S19e Proteins 0.000 description 1
• 101001114407 Haloarcula marismortui (strain ATCC 43049 / DSM 3752 / JCM 8966 / VKM B-1809) 30S ribosomal protein S6e Proteins 0.000 description 1
• 101000718286 Halobacterium salinarum (strain ATCC 700922 / JCM 11081 / NRC-1) 30S ribosomal protein S13 Proteins 0.000 description 1
• 208000030836 Hashimoto thyroiditis Diseases 0.000 description 1
• 102000002812 Heat-Shock Proteins Human genes 0.000 description 1
• 108010004889 Heat-Shock Proteins Proteins 0.000 description 1
• 208000035186 Hemolytic Autoimmune Anemia Diseases 0.000 description 1
• 206010019755 Hepatitis chronic active Diseases 0.000 description 1
• 206010020112 Hirsutism Diseases 0.000 description 1
• 241000282412 Homo Species 0.000 description 1
• 101100005713 Homo sapiens CD4 gene Proteins 0.000 description 1
• 101001082627 Homo sapiens HLA class II histocompatibility antigen gamma chain Proteins 0.000 description 1
• 101001076407 Homo sapiens Interleukin-1 receptor antagonist protein Proteins 0.000 description 1
• 101000764622 Homo sapiens Transmembrane and immunoglobulin domain-containing protein 2 Proteins 0.000 description 1
• 241000701109 Human adenovirus 2 Species 0.000 description 1
• 206010020649 Hyperkeratosis Diseases 0.000 description 1
• 206010020772 Hypertension Diseases 0.000 description 1
• HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 1
• 206010021245 Idiopathic thrombocytopenic purpura Diseases 0.000 description 1
• 206010061598 Immunodeficiency Diseases 0.000 description 1
• 208000029462 Immunodeficiency disease Diseases 0.000 description 1
• 108010021625 Immunoglobulin Fragments Proteins 0.000 description 1
• 102000008394 Immunoglobulin Fragments Human genes 0.000 description 1
• 206010022489 Insulin Resistance Diseases 0.000 description 1
• 108010005714 Interferon beta-1b Proteins 0.000 description 1
• 229940119178 Interleukin 1 receptor antagonist Drugs 0.000 description 1
• 108010038453 Interleukin-2 Receptors Proteins 0.000 description 1
• 102000010789 Interleukin-2 Receptors Human genes 0.000 description 1
• PIWKPBJCKXDKJR-UHFFFAOYSA-N Isoflurane Chemical compound FC(F)OC(Cl)C(F)(F)F PIWKPBJCKXDKJR-UHFFFAOYSA-N 0.000 description 1
• 108010025815 Kanamycin Kinase Proteins 0.000 description 1
• YQEZLKZALYSWHR-UHFFFAOYSA-N Ketamine Chemical compound C=1C=CC=C(Cl)C=1C1(NC)CCCCC1=O YQEZLKZALYSWHR-UHFFFAOYSA-N 0.000 description 1
• 241000235058 Komagataella pastoris Species 0.000 description 1
• ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
• AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 1
• KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
• FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
• GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
• 108010052014 Liberase Proteins 0.000 description 1
• 208000005777 Lupus Nephritis Diseases 0.000 description 1
• 241000282553 Macaca Species 0.000 description 1
• MQHWFIOJQSCFNM-UHFFFAOYSA-L Magnesium salicylate Chemical compound [Mg+2].OC1=CC=CC=C1C([O-])=O.OC1=CC=CC=C1C([O-])=O MQHWFIOJQSCFNM-UHFFFAOYSA-L 0.000 description 1
• GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
• 238000000585 Mann–Whitney U test Methods 0.000 description 1
• SBDNJUWAMKYJOX-UHFFFAOYSA-N Meclofenamic Acid Chemical compound CC1=CC=C(Cl)C(NC=2C(=CC=CC=2)C(O)=O)=C1Cl SBDNJUWAMKYJOX-UHFFFAOYSA-N 0.000 description 1
• 102000018697 Membrane Proteins Human genes 0.000 description 1
• 108010052285 Membrane Proteins Proteins 0.000 description 1
• 208000003250 Mixed connective tissue disease Diseases 0.000 description 1
• 239000004909 Moisturizer Substances 0.000 description 1
• 241001529936 Murinae Species 0.000 description 1
• 206010028665 Myxoedema Diseases 0.000 description 1
• BLXXJMDCKKHMKV-UHFFFAOYSA-N Nabumetone Chemical compound C1=C(CCC(C)=O)C=CC2=CC(OC)=CC=C21 BLXXJMDCKKHMKV-UHFFFAOYSA-N 0.000 description 1
• CMWTZPSULFXXJA-UHFFFAOYSA-N Naproxen Natural products C1=C(C(C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-UHFFFAOYSA-N 0.000 description 1
• 206010029155 Nephropathy toxic Diseases 0.000 description 1
• 244000061176 Nicotiana tabacum Species 0.000 description 1
• 235000002637 Nicotiana tabacum Nutrition 0.000 description 1
• 229910019142 PO4 Inorganic materials 0.000 description 1
• 241001494479 Pecora Species 0.000 description 1
• 241000721454 Pemphigus Species 0.000 description 1
• 108010087702 Penicillinase Proteins 0.000 description 1
• 108010033276 Peptide Fragments Proteins 0.000 description 1
• 102000007079 Peptide Fragments Human genes 0.000 description 1
• 208000031845 Pernicious anaemia Diseases 0.000 description 1
• 108091000080 Phosphotransferase Proteins 0.000 description 1
• 206010035226 Plasma cell myeloma Diseases 0.000 description 1
• 239000002202 Polyethylene glycol Substances 0.000 description 1
• 208000012654 Primary biliary cholangitis Diseases 0.000 description 1
• 102000007327 Protamines Human genes 0.000 description 1
• 108010007568 Protamines Proteins 0.000 description 1
• 239000012979 RPMI medium Substances 0.000 description 1
• 241000235347 Schizosaccharomyces pombe Species 0.000 description 1
• 206010039710 Scleroderma Diseases 0.000 description 1
• 208000021386 Sjogren Syndrome Diseases 0.000 description 1
• ABBQHOQBGMUPJH-UHFFFAOYSA-M Sodium salicylate Chemical compound [Na+].OC1=CC=CC=C1C([O-])=O ABBQHOQBGMUPJH-UHFFFAOYSA-M 0.000 description 1
• ZSJLQEPLLKMAKR-UHFFFAOYSA-N Streptozotocin Natural products O=NN(C)C(=O)NC1C(O)OC(CO)C(O)C1O ZSJLQEPLLKMAKR-UHFFFAOYSA-N 0.000 description 1
• 206010042742 Sympathetic ophthalmia Diseases 0.000 description 1
• 230000006044 T cell activation Effects 0.000 description 1
• 230000017274 T cell anergy Effects 0.000 description 1
• 108091008874 T cell receptors Proteins 0.000 description 1
• 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 1
• 206010042971 T-cell lymphoma Diseases 0.000 description 1
• 208000027585 T-cell non-Hodgkin lymphoma Diseases 0.000 description 1
• 101710180188 T-lymphocyte activation antigen CD80 Proteins 0.000 description 1
• 102100034924 T-lymphocyte activation antigen CD86 Human genes 0.000 description 1
• 108091036066 Three prime untranslated region Proteins 0.000 description 1
• JLRGJRBPOGGCBT-UHFFFAOYSA-N Tolbutamide Chemical compound CCCCNC(=O)NS(=O)(=O)C1=CC=C(C)C=C1 JLRGJRBPOGGCBT-UHFFFAOYSA-N 0.000 description 1
• 102100026224 Transmembrane and immunoglobulin domain-containing protein 2 Human genes 0.000 description 1
• 239000007983 Tris buffer Substances 0.000 description 1
• 108060008683 Tumor Necrosis Factor Receptor Proteins 0.000 description 1
• 208000035896 Twin-reversed arterial perfusion sequence Diseases 0.000 description 1
• 201000006704 Ulcerative Colitis Diseases 0.000 description 1
• 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
• 235000016383 Zea mays subsp huehuetenangensis Nutrition 0.000 description 1
• 210000000683 abdominal cavity Anatomy 0.000 description 1
• 230000003187 abdominal effect Effects 0.000 description 1
• NFXWJYUDIOHFAW-UHFFFAOYSA-N acetic acid;tetradecanoic acid Chemical compound CC(O)=O.CCCCCCCCCCCCCC(O)=O NFXWJYUDIOHFAW-UHFFFAOYSA-N 0.000 description 1
• 239000004480 active ingredient Substances 0.000 description 1
• 230000001154 acute effect Effects 0.000 description 1
• 208000037833 acute lymphoblastic T-cell leukemia Diseases 0.000 description 1
• 238000001042 affinity chromatography Methods 0.000 description 1
• 229940100198 alkylating agent Drugs 0.000 description 1
• 239000002168 alkylating agent Substances 0.000 description 1
• WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 description 1
• PNEYBMLMFCGWSK-UHFFFAOYSA-N aluminium oxide Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 1
• 229960000723 ampicillin Drugs 0.000 description 1
• AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 1
• 238000010171 animal model Methods 0.000 description 1
• 229940121363 anti-inflammatory agent Drugs 0.000 description 1
• 238000011861 anti-inflammatory therapy Methods 0.000 description 1
• 230000000781 anti-lymphocytic effect Effects 0.000 description 1
• 230000001494 anti-thymocyte effect Effects 0.000 description 1
• 210000003293 antilymphocyte serum Anatomy 0.000 description 1
• 210000000709 aorta Anatomy 0.000 description 1
• 229940059756 arava Drugs 0.000 description 1
• 230000001363 autoimmune Effects 0.000 description 1
• 201000000448 autoimmune hemolytic anemia Diseases 0.000 description 1
• 201000003710 autoimmune thrombocytopenic purpura Diseases 0.000 description 1
• 201000004982 autoimmune uveitis Diseases 0.000 description 1
• 230000005784 autoimmunity Effects 0.000 description 1
• 230000004888 barrier function Effects 0.000 description 1
• 210000000227 basophil cell of anterior lobe of hypophysis Anatomy 0.000 description 1
• 239000011324 bead Substances 0.000 description 1
• IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 1
• GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
• 108091008324 binding proteins Proteins 0.000 description 1
• 230000009287 biochemical signal transduction Effects 0.000 description 1
• 230000004071 biological effect Effects 0.000 description 1
• 230000015572 biosynthetic process Effects 0.000 description 1
• 239000002981 blocking agent Substances 0.000 description 1
• 210000000601 blood cell Anatomy 0.000 description 1
• 210000000988 bone and bone Anatomy 0.000 description 1
• 238000010322 bone marrow transplantation Methods 0.000 description 1
• 235000021152 breakfast Nutrition 0.000 description 1
• 239000000872 buffer Substances 0.000 description 1
• 239000008366 buffered solution Substances 0.000 description 1
• 239000001506 calcium phosphate Substances 0.000 description 1
• 229910000389 calcium phosphate Inorganic materials 0.000 description 1
• 235000011010 calcium phosphates Nutrition 0.000 description 1
• 201000011510 cancer Diseases 0.000 description 1
• 230000015556 catabolic process Effects 0.000 description 1
• 238000004113 cell culture Methods 0.000 description 1
• 239000006143 cell culture medium Substances 0.000 description 1
• 239000006285 cell suspension Substances 0.000 description 1
• 230000005754 cellular signaling Effects 0.000 description 1
• 239000001913 cellulose Substances 0.000 description 1
• 229920002678 cellulose Polymers 0.000 description 1
• 238000012512 characterization method Methods 0.000 description 1
• 239000007795 chemical reaction product Substances 0.000 description 1
• 208000016644 chronic atrophic gastritis Diseases 0.000 description 1
• 208000025302 chronic primary adrenal insufficiency Diseases 0.000 description 1
• 238000011260 co-administration Methods 0.000 description 1
• 230000001427 coherent effect Effects 0.000 description 1
• 230000000052 comparative effect Effects 0.000 description 1
• 230000004154 complement system Effects 0.000 description 1
• 239000003636 conditioned culture medium Substances 0.000 description 1
• 230000001143 conditioned effect Effects 0.000 description 1
• 235000005822 corn Nutrition 0.000 description 1
• 230000004940 costimulation Effects 0.000 description 1
• 230000008878 coupling Effects 0.000 description 1
• 238000010168 coupling process Methods 0.000 description 1
• 238000005859 coupling reaction Methods 0.000 description 1
• 229940109239 creatinine Drugs 0.000 description 1
• 229940064774 cuprimine Drugs 0.000 description 1
• 230000001086 cytosolic effect Effects 0.000 description 1
• 231100000433 cytotoxic Toxicity 0.000 description 1
• 230000001472 cytotoxic effect Effects 0.000 description 1
• 238000013461 design Methods 0.000 description 1
• 238000001514 detection method Methods 0.000 description 1
• 229960001259 diclofenac Drugs 0.000 description 1
• DCOPUUMXTXDBNB-UHFFFAOYSA-N diclofenac Chemical compound OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl DCOPUUMXTXDBNB-UHFFFAOYSA-N 0.000 description 1
• 238000009792 diffusion process Methods 0.000 description 1
• 229960000616 diflunisal Drugs 0.000 description 1
• HUPFGZXOMWLGNK-UHFFFAOYSA-N diflunisal Chemical compound C1=C(O)C(C(=O)O)=CC(C=2C(=CC(F)=CC=2)F)=C1 HUPFGZXOMWLGNK-UHFFFAOYSA-N 0.000 description 1
• 238000006471 dimerization reaction Methods 0.000 description 1
• 208000035475 disorder Diseases 0.000 description 1
• 239000002552 dosage form Substances 0.000 description 1
• 238000001647 drug administration Methods 0.000 description 1
• 230000002183 duodenal effect Effects 0.000 description 1
• 230000004064 dysfunction Effects 0.000 description 1
• 239000003792 electrolyte Substances 0.000 description 1
• 230000008030 elimination Effects 0.000 description 1
• 238000003379 elimination reaction Methods 0.000 description 1
• 229940073621 enbrel Drugs 0.000 description 1
• 238000005516 engineering process Methods 0.000 description 1
• 239000003623 enhancer Substances 0.000 description 1
• 230000007613 environmental effect Effects 0.000 description 1
• 238000003114 enzyme-linked immunosorbent spot assay Methods 0.000 description 1
• 150000002148 esters Chemical class 0.000 description 1
• BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
• 229960005293 etodolac Drugs 0.000 description 1
• XFBVBWWRPKNWHW-UHFFFAOYSA-N etodolac Chemical compound C1COC(CC)(CC(O)=O)C2=N[C]3C(CC)=CC=CC3=C21 XFBVBWWRPKNWHW-UHFFFAOYSA-N 0.000 description 1
• 230000001610 euglycemic effect Effects 0.000 description 1
• 229960001419 fenoprofen Drugs 0.000 description 1
• 238000001943 fluorescence-activated cell sorting Methods 0.000 description 1
• 229960002390 flurbiprofen Drugs 0.000 description 1
• SYTBZMRGLBWNTM-UHFFFAOYSA-N flurbiprofen Chemical compound FC1=CC(C(C(O)=O)C)=CC=C1C1=CC=CC=C1 SYTBZMRGLBWNTM-UHFFFAOYSA-N 0.000 description 1
• 238000009472 formulation Methods 0.000 description 1
• 238000011990 functional testing Methods 0.000 description 1
• 229930182830 galactose Natural products 0.000 description 1
• 238000005227 gel permeation chromatography Methods 0.000 description 1
• 238000001415 gene therapy Methods 0.000 description 1
• 238000002695 general anesthesia Methods 0.000 description 1
• 230000002068 genetic effect Effects 0.000 description 1
• 239000011521 glass Substances 0.000 description 1
• PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
• 239000010931 gold Substances 0.000 description 1
• 229910052737 gold Inorganic materials 0.000 description 1
• 230000005484 gravity Effects 0.000 description 1
• 238000003306 harvesting Methods 0.000 description 1
• 208000034737 hemoglobinopathy Diseases 0.000 description 1
• 210000003494 hepatocyte Anatomy 0.000 description 1
• 230000013632 homeostatic process Effects 0.000 description 1
• 102000043321 human CTLA4 Human genes 0.000 description 1
• 230000003345 hyperglycaemic effect Effects 0.000 description 1
• 229960001680 ibuprofen Drugs 0.000 description 1
• 238000003384 imaging method Methods 0.000 description 1
• 238000003119 immunoblot Methods 0.000 description 1
• 230000007813 immunodeficiency Effects 0.000 description 1
• 230000002998 immunogenetic effect Effects 0.000 description 1
• 239000002955 immunomodulating agent Substances 0.000 description 1
• 238000012744 immunostaining Methods 0.000 description 1
• 229960003444 immunosuppressant agent Drugs 0.000 description 1
• 230000001861 immunosuppressant effect Effects 0.000 description 1
• 238000002650 immunosuppressive therapy Methods 0.000 description 1
• 230000002637 immunotoxin Effects 0.000 description 1
• 239000002596 immunotoxin Substances 0.000 description 1
• 231100000608 immunotoxin Toxicity 0.000 description 1
• 229940051026 immunotoxin Drugs 0.000 description 1
• 238000002513 implantation Methods 0.000 description 1
• 238000001727 in vivo Methods 0.000 description 1
• 230000000415 inactivating effect Effects 0.000 description 1
• 229960000905 indomethacin Drugs 0.000 description 1
• 208000027866 inflammatory disease Diseases 0.000 description 1
• 208000018337 inherited hemoglobinopathy Diseases 0.000 description 1
• 238000003780 insertion Methods 0.000 description 1
• 230000037431 insertion Effects 0.000 description 1
• 230000002452 interceptive effect Effects 0.000 description 1
• 229960003161 interferon beta-1b Drugs 0.000 description 1
• 229960003130 interferon gamma Drugs 0.000 description 1
• 239000003407 interleukin 1 receptor blocking agent Substances 0.000 description 1
• 238000004255 ion exchange chromatography Methods 0.000 description 1
• 150000002500 ions Chemical class 0.000 description 1
• 229960002725 isoflurane Drugs 0.000 description 1
• 229960000318 kanamycin Drugs 0.000 description 1
• 229930027917 kanamycin Natural products 0.000 description 1
• SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 1
• 229930182823 kanamycin A Natural products 0.000 description 1
• 229960003299 ketamine Drugs 0.000 description 1
• DKYWVDODHFEZIM-UHFFFAOYSA-N ketoprofen Chemical compound OC(=O)C(C)C1=CC=CC(C(=O)C=2C=CC=CC=2)=C1 DKYWVDODHFEZIM-UHFFFAOYSA-N 0.000 description 1
• 229960000991 ketoprofen Drugs 0.000 description 1
• 229960004752 ketorolac Drugs 0.000 description 1
• OZWKMVRBQXNZKK-UHFFFAOYSA-N ketorolac Chemical compound OC(=O)C1CCN2C1=CC=C2C(=O)C1=CC=CC=C1 OZWKMVRBQXNZKK-UHFFFAOYSA-N 0.000 description 1
• 208000017169 kidney disease Diseases 0.000 description 1
• 229940054136 kineret Drugs 0.000 description 1
• 239000008101 lactose Substances 0.000 description 1
• 229940067606 lecithin Drugs 0.000 description 1
• 235000010445 lecithin Nutrition 0.000 description 1
• 239000000787 lecithin Substances 0.000 description 1
• 210000000566 lesser sac Anatomy 0.000 description 1
• 150000002614 leucines Chemical class 0.000 description 1
• 230000021633 leukocyte mediated immunity Effects 0.000 description 1
• 210000003041 ligament Anatomy 0.000 description 1
• 230000037356 lipid metabolism Effects 0.000 description 1
• 150000002632 lipids Chemical class 0.000 description 1
• 239000006193 liquid solution Substances 0.000 description 1
• 239000006194 liquid suspension Substances 0.000 description 1
• 238000012153 long-term therapy Methods 0.000 description 1
• 210000004072 lung Anatomy 0.000 description 1
• 210000001165 lymph node Anatomy 0.000 description 1
• 230000000527 lymphocytic effect Effects 0.000 description 1
• 230000002101 lytic effect Effects 0.000 description 1
• 239000003120 macrolide antibiotic agent Substances 0.000 description 1
• 229920002521 macromolecule Polymers 0.000 description 1
• 229940072082 magnesium salicylate Drugs 0.000 description 1
• 239000006249 magnetic particle Substances 0.000 description 1
• 235000009973 maize Nutrition 0.000 description 1
• 230000036210 malignancy Effects 0.000 description 1
• 230000013011 mating Effects 0.000 description 1
• 238000005259 measurement Methods 0.000 description 1
• 238000010297 mechanical methods and process Methods 0.000 description 1
• 229940013798 meclofenamate Drugs 0.000 description 1
• 239000012528 membrane Substances 0.000 description 1
• 210000004379 membrane Anatomy 0.000 description 1
• 230000008384 membrane barrier Effects 0.000 description 1
• 210000001758 mesenteric vein Anatomy 0.000 description 1
• 108020004999 messenger RNA Proteins 0.000 description 1
• 208000030159 metabolic disease Diseases 0.000 description 1
• 230000002503 metabolic effect Effects 0.000 description 1
• 230000000813 microbial effect Effects 0.000 description 1
• 239000003094 microcapsule Substances 0.000 description 1
• 239000004005 microsphere Substances 0.000 description 1
• 238000002156 mixing Methods 0.000 description 1
• 238000012986 modification Methods 0.000 description 1
• 230000004048 modification Effects 0.000 description 1
• 230000001333 moisturizer Effects 0.000 description 1
• 238000010369 molecular cloning Methods 0.000 description 1
• 238000012544 monitoring process Methods 0.000 description 1
• 201000006417 multiple sclerosis Diseases 0.000 description 1
• 210000003205 muscle Anatomy 0.000 description 1
• 231100000219 mutagenic Toxicity 0.000 description 1
• 230000003505 mutagenic effect Effects 0.000 description 1
• 206010028417 myasthenia gravis Diseases 0.000 description 1
• 201000000050 myeloid neoplasm Diseases 0.000 description 1
• 208000003786 myxedema Diseases 0.000 description 1
• BLUYEPLOXLPVCJ-INIZCTEOSA-N n-[(1s)-2-[4-(3-aminopropylamino)butylamino]-1-hydroxyethyl]-7-(diaminomethylideneamino)heptanamide Chemical compound NCCCNCCCCNC[C@H](O)NC(=O)CCCCCCNC(N)=N BLUYEPLOXLPVCJ-INIZCTEOSA-N 0.000 description 1
• 229960004270 nabumetone Drugs 0.000 description 1
• 229960002009 naproxen Drugs 0.000 description 1
• CMWTZPSULFXXJA-VIFPVBQESA-N naproxen Chemical compound C1=C([C@H](C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-VIFPVBQESA-N 0.000 description 1
• 230000025020 negative regulation of T cell proliferation Effects 0.000 description 1
• 229940063121 neoral Drugs 0.000 description 1
• 230000007694 nephrotoxicity Effects 0.000 description 1
• 231100000417 nephrotoxicity Toxicity 0.000 description 1
• 210000002569 neuron Anatomy 0.000 description 1
• 230000007935 neutral effect Effects 0.000 description 1
• 229910052757 nitrogen Inorganic materials 0.000 description 1
• 231100000252 nontoxic Toxicity 0.000 description 1
• 230000003000 nontoxic effect Effects 0.000 description 1
• 230000008816 organ damage Effects 0.000 description 1
• 210000001672 ovary Anatomy 0.000 description 1
• 210000004923 pancreatic tissue Anatomy 0.000 description 1
• 229960005489 paracetamol Drugs 0.000 description 1
• 230000036961 partial effect Effects 0.000 description 1
• 230000007170 pathology Effects 0.000 description 1
• 229950009506 penicillinase Drugs 0.000 description 1
• 230000002093 peripheral effect Effects 0.000 description 1
• 239000008177 pharmaceutical agent Substances 0.000 description 1
• 229960002895 phenylbutazone Drugs 0.000 description 1
• VYMDGNCVAMGZFE-UHFFFAOYSA-N phenylbutazonum Chemical compound O=C1C(CCCC)C(=O)N(C=2C=CC=CC=2)N1C1=CC=CC=C1 VYMDGNCVAMGZFE-UHFFFAOYSA-N 0.000 description 1
• 235000021317 phosphate Nutrition 0.000 description 1
• 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
• 102000020233 phosphotransferase Human genes 0.000 description 1
• 239000006187 pill Substances 0.000 description 1
• 229960002702 piroxicam Drugs 0.000 description 1
• QYSPLQLAKJAUJT-UHFFFAOYSA-N piroxicam Chemical compound OC=1C2=CC=CC=C2S(=O)(=O)N(C)C=1C(=O)NC1=CC=CC=N1 QYSPLQLAKJAUJT-UHFFFAOYSA-N 0.000 description 1
• 229940072689 plaquenil Drugs 0.000 description 1
• 210000001778 pluripotent stem cell Anatomy 0.000 description 1
• 229920001223 polyethylene glycol Polymers 0.000 description 1
• 238000003752 polymerase chain reaction Methods 0.000 description 1
• 208000005987 polymyositis Diseases 0.000 description 1
• 210000003240 portal vein Anatomy 0.000 description 1
• 230000002980 postoperative effect Effects 0.000 description 1
• 230000000291 postprandial effect Effects 0.000 description 1
• 235000010241 potassium sorbate Nutrition 0.000 description 1
• 239000004302 potassium sorbate Substances 0.000 description 1
• 229940069338 potassium sorbate Drugs 0.000 description 1
• 239000000843 powder Substances 0.000 description 1
• 230000002265 prevention Effects 0.000 description 1
• 238000011809 primate model Methods 0.000 description 1
• 229940072288 prograf Drugs 0.000 description 1
• 230000002035 prolonged effect Effects 0.000 description 1
• 229950008679 protamine sulfate Drugs 0.000 description 1
• 239000013636 protein dimer Substances 0.000 description 1
• 238000000164 protein isolation Methods 0.000 description 1
• 238000000746 purification Methods 0.000 description 1
• 238000011002 quantification Methods 0.000 description 1
• 230000009257 reactivity Effects 0.000 description 1
• 230000009467 reduction Effects 0.000 description 1
• 230000012121 regulation of immune response Effects 0.000 description 1
• 230000022532 regulation of transcription, DNA-dependent Effects 0.000 description 1
• 108091008146 restriction endonucleases Proteins 0.000 description 1
• 230000001177 retroviral effect Effects 0.000 description 1
• 229960000953 salsalate Drugs 0.000 description 1
• 230000003248 secreting effect Effects 0.000 description 1
• 210000002966 serum Anatomy 0.000 description 1
• 230000035939 shock Effects 0.000 description 1
• 238000002741 site-directed mutagenesis Methods 0.000 description 1
• 210000003491 skin Anatomy 0.000 description 1
• 150000003384 small molecules Chemical class 0.000 description 1
• 229960004025 sodium salicylate Drugs 0.000 description 1
• 239000007787 solid Substances 0.000 description 1
• 235000010199 sorbic acid Nutrition 0.000 description 1
• 229940075582 sorbic acid Drugs 0.000 description 1
• 239000004334 sorbic acid Substances 0.000 description 1
• 230000009870 specific binding Effects 0.000 description 1
• 210000000952 spleen Anatomy 0.000 description 1
• 238000010911 splenectomy Methods 0.000 description 1
• 210000002563 splenic artery Anatomy 0.000 description 1
• 210000000955 splenic vein Anatomy 0.000 description 1
• 230000000087 stabilizing effect Effects 0.000 description 1
• 238000010561 standard procedure Methods 0.000 description 1
• 238000007619 statistical method Methods 0.000 description 1
• 150000003431 steroids Chemical group 0.000 description 1
• 238000003860 storage Methods 0.000 description 1
• 229960001052 streptozocin Drugs 0.000 description 1
• ZSJLQEPLLKMAKR-GKHCUFPYSA-N streptozocin Chemical compound O=NN(C)C(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O ZSJLQEPLLKMAKR-GKHCUFPYSA-N 0.000 description 1
• 238000012916 structural analysis Methods 0.000 description 1
• 239000000758 substrate Substances 0.000 description 1
• 229960000894 sulindac Drugs 0.000 description 1
• MLKXDPUZXIRXEP-MFOYZWKCSA-N sulindac Chemical compound CC1=C(CC(O)=O)C2=CC(F)=CC=C2\C1=C/C1=CC=C(S(C)=O)C=C1 MLKXDPUZXIRXEP-MFOYZWKCSA-N 0.000 description 1
• 239000013589 supplement Substances 0.000 description 1
• 238000001356 surgical procedure Methods 0.000 description 1
• 230000002195 synergetic effect Effects 0.000 description 1
• 230000009885 systemic effect Effects 0.000 description 1
• 239000003826 tablet Substances 0.000 description 1
• 230000008685 targeting Effects 0.000 description 1
• 230000002381 testicular Effects 0.000 description 1
• 229940126585 therapeutic drug Drugs 0.000 description 1
• 229940113082 thymine Drugs 0.000 description 1
• 229960001017 tolmetin Drugs 0.000 description 1
• UPSPUYADGBWSHF-UHFFFAOYSA-N tolmetin Chemical compound C1=CC(C)=CC=C1C(=O)C1=CC=C(CC(O)=O)N1C UPSPUYADGBWSHF-UHFFFAOYSA-N 0.000 description 1
• 229960004380 tramadol Drugs 0.000 description 1
• TVYLLZQTGLZFBW-GOEBONIOSA-N tramadol Natural products COC1=CC=CC([C@@]2(O)[C@@H](CCCC2)CN(C)C)=C1 TVYLLZQTGLZFBW-GOEBONIOSA-N 0.000 description 1
• 230000005026 transcription initiation Effects 0.000 description 1
• 238000010361 transduction Methods 0.000 description 1
• 230000026683 transduction Effects 0.000 description 1
• 230000009466 transformation Effects 0.000 description 1
• 238000000844 transformation Methods 0.000 description 1
• 230000001052 transient effect Effects 0.000 description 1
• QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
• LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
• FQCQGOZEWWPOKI-UHFFFAOYSA-K trisalicylate-choline Chemical compound [Mg+2].C[N+](C)(C)CCO.OC1=CC=CC=C1C([O-])=O.OC1=CC=CC=C1C([O-])=O.OC1=CC=CC=C1C([O-])=O FQCQGOZEWWPOKI-UHFFFAOYSA-K 0.000 description 1
• 102000003298 tumor necrosis factor receptor Human genes 0.000 description 1
• WFKWXMTUELFFGS-UHFFFAOYSA-N tungsten Chemical compound [W] WFKWXMTUELFFGS-UHFFFAOYSA-N 0.000 description 1
• 229910052721 tungsten Inorganic materials 0.000 description 1
• 239000010937 tungsten Substances 0.000 description 1
• 241000701447 unidentified baculovirus Species 0.000 description 1
• 238000011144 upstream manufacturing Methods 0.000 description 1
• 239000013603 viral vector Substances 0.000 description 1
• 230000003612 virological effect Effects 0.000 description 1
• 239000011240 wet gel Substances 0.000 description 1
• 239000000080 wetting agent Substances 0.000 description 1